c-Met plays an important role in colorectal
tumorigenesis and
disease progression and thus is believed to be an attractive inhibitory target for receptor molecular therapeutic.
SU11274 was identified as a small molecule,
ATP competitive inhibitor of the catalytic activity of the c-Met
kinase. Our study had investigated the relationship between the high expression of c-Met and
colorectal carcinoma and the effect of c-Met inhibitor
SU11274 in
colorectal carcinoma in vitro and vivo. Immunohistochemistry was used to detect the expression of c-Met in 60 patients with
colorectal cancer and 20 patients with benign
adenoma and surrounding normal colon tissues. The effect of
SU11274 on human
colorectal carcinoma LoVo cells was detected by Western blot and MTT. And the influence of
SU11274 on cell cycle was determined by flow cytometry. In addition, LoVo cell-transplanted
tumor growth and expression of c-Met in nude mice was examined for inhibition of
SU11274 in vivo. We found c-Met had high expression and was closely related to
lymph node metastasis and TNM stage in
colorectal carcinoma tissues.
SU11274 significantly suppressed the phosphorylation of c-Met as well as the survival and proliferation of LoVo cell lines. G1-phase arrest was also induced by
SU11274.
SU11274 apparently restrained the growth of the xenograft
tumor in nude mice. Our data suggest developing
therapies that specifically inhibit the activation of c-Met may represent a novel therapeutic modality for patients with
colorectal carcinoma expressing high levels of c-Met.